Chronotherapy Of Hypertension In Obstructive Sleep Apnoea
Funder
National Health and Medical Research Council
Funding Amount
$232,738.00
Summary
Obstructive Sleep Apnoea (OSA) is linked with excess cardiovascular disease, and this is partly attributed to increased high blood pressure (hypertension). Understanding how both conditions exacerbate hypertension and whether blood pressure control can be improved by altering the time that medication is taken will lead to improvements in health.
Cardiometabolic Changes After Continuous Positive Airway Pressure Treatment For Obstructive Sleep Apnea
Funder
National Health and Medical Research Council
Funding Amount
$82,421.00
Summary
CPAP is the preferred treatment for patients with OSA because of its well-proven ability to decrease sleepiness and improve blood pressure control. This study will definitively establish if CPAP can also improve markers of cardio-metabolic health, such as visceral fat, insulin sensitivity, central blood pressure and arterial stiffness. The results of the study will shed light on the broader health consequences of OSA and contributes to the development of more targeted treatment strategies.
Metabolic And Neurobiological Changes After Continuous Positive Airway Pressure Treatment For Obstructive Sleep Apnea
Funder
National Health and Medical Research Council
Funding Amount
$503,497.00
Summary
CPAP is the preferred treatment for patients with OSA because of its well-proven ability to decrease sleepiness and improve blood pressure control. This study will definitively establish if CPAP can also improve markers of cardio-metabolic health, such as visceral fat, insulin sensitivity, central blood pressure and arterial stiffness. The results of the study will shed light on the broader health consequences of OSA and contribute to the development of more targeted treatment strategies.
Chronotherapy For Hypertension In Obstructive Sleep Apnea
Funder
National Health and Medical Research Council
Funding Amount
$253,229.00
Summary
Obstructive Sleep Apnea (OSA) is a common cause of hypertension, however treatment of OSA only results in a modest improvement in blood pressure (BP) and patients who are unable to tolerate treatment must rely on pharmacotherapy to control their BP. This study will definitively establish if altering the time of taking medication can improve BP control over 24 hours. The results will conribute to the development of more targeted treatment strategies for hypertension in people with OSA.
Functional Characterisation Of Novel Metabolites In Asthma And Identification Of New Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$829,922.00
Summary
Asthma is a chronic inflammatory disease of the airways that represents a major health burden. Severe asthma represents 10% of those suffering the disease and poses an urgent problem due to exacerbations and resistance to current therapies. We have conducted the first study of the metabolites that are altered in the airways of patients with severe asthma and identified functional metabolites and disease biomarkers. We now aim to assess the function of these molecules in asthma disease models.
We will conduct a survey of respiratory symptoms, lung function, smoking status, occupational exposures, and other risk factors among 3200 people aged 40 years and over living in five Australian communities: Melbourne, Sydney, Tasmania, Busselton (WA), and the Kimberley region (WA). In the Kimberley we will survey 400 Aboriginal people and 400 non-Aboriginal people. We will use a survey methodology that has been developed by an international expert panel and has been implemented in many other co ....We will conduct a survey of respiratory symptoms, lung function, smoking status, occupational exposures, and other risk factors among 3200 people aged 40 years and over living in five Australian communities: Melbourne, Sydney, Tasmania, Busselton (WA), and the Kimberley region (WA). In the Kimberley we will survey 400 Aboriginal people and 400 non-Aboriginal people. We will use a survey methodology that has been developed by an international expert panel and has been implemented in many other countries (in North and South America, Asia, and Europe). This study will provide the first nationally-representative information on the burden of chronic obstructive pulmonary disease (COPD) and the opportunities for health gain by improving the management of this illness. In Australia, COPD is a relatively silent and under-recognised disease but nevertheless is the third most important contributor to the burden of disease and the third leading cause of hospital admission as well as being the underlying cause of 4.2% of all deaths. The information we will collect is needed to form a basis for prevention and disease management interventions to reduce the burden of COPD, particularly among population sub-groups who are disproportionately affected, either due to greater exposure to risk factors (mainly tobacco smoking and occupation), greater susceptibility, under-recognition and under-diagnosis, or inadequate disease management. Importantly, the study will serve to raise awareness about the hazards of smoking for all Australians. By identifying target groups, prevalent exposures and management deficiencies, it will lead the way towards policy-relevant randomised controlled trials testing community-based interventions to prevent COPD and-or manage it more effectively. The information collected will help advance knowledge of the prevalence, burden and treatment of COPD that will be relevant to communities throughout the world.Read moreRead less
The Emerging Problem Of Non-tuberculous Mycobacteria Infection: Understanding Aetiology, Geospatial Epidemiology And Developing Interventions
Funder
National Health and Medical Research Council
Funding Amount
$988,791.00
Summary
This project will be largest study of non-tuberculous mycobacterial (NTM) infection in cystic fibrosis. By combining growing the bacteria with detailed information from the CF patient data registry, geographical location and environmental conditions, this study will provide novel insights into factors associated with NTM. Gene sequencing and airway infection profiling will extend understanding and has the potential to identify novel risk factors and biomarkers for NTM-related airways disease.